[{"address1": "Clarence Thomas Building", "address2": "P.O. Box 4649 Road Town", "city": "Tortola", "zip": "VG1110", "country": "British Virgin Islands", "phone": "302 219 5556", "website": "https://www.portagebiotech.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Portage Biotech Inc., a clinical stage immune-oncology company, engages in the research and develops pharmaceutical and biotechnology products. Its product pipeline comprises PORT-3, a polylactide-co-glycolide, which is in phase 1 to treat NY-ESO-1 positive tumors; PORT-6, a highly selective A2A receptor antagonist, which is in phase 1a for the treatment of solid tumors; PORT-8, a dual inhibitor of adenosine receptors 2A and 2B, which is in preclinical trial to treat solid tumors; PORT-9, an A2B antagonist, which is in pre-clinical stage program to treat colorectal and gastrointestinal cancers; PORT-4, a nanolipogel co-formulations to treat of solid tumors that is in preclinical trials; PORT-5, a VLP-STING to treat of solid tumors and is in preclinical trials; and PORT-7, a potent and selective antagonist of the adenosine A2B receptor. Portage Biotech Inc. is based in Tortola, British Virgin Islands.", "fullTimeEmployees": 3, "companyOfficers": [{"maxAge": 1, "name": "Adam  Melero", "title": "Controller", "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Peter  Molloy", "title": "Chief Executive Officer of Cyncado Therapeutics Inc.", "exercisedValue": 0, "unexercisedValue": 0}], "executiveTeam": [], "maxAge": 86400, "priceHint": 2, "previousClose": 6.96, "open": 7.6, "dayLow": 6.8005, "dayHigh": 9.43, "regularMarketPreviousClose": 6.96, "regularMarketOpen": 7.6, "regularMarketDayLow": 6.8005, "regularMarketDayHigh": 9.43, "payoutRatio": 0.0, "beta": 0.637, "forwardPE": -13.096154, "volume": 371668, "regularMarketVolume": 371668, "averageVolume": 121179, "averageVolume10days": 122497, "averageDailyVolume10Day": 122497, "bid": 0.0, "ask": 0.0, "bidSize": 0, "askSize": 0, "marketCap": 15517402, "fiftyTwoWeekLow": 2.95, "fiftyTwoWeekHigh": 15.8181, "allTimeHigh": 114618.055, "allTimeLow": 0.2, "fiftyDayAverage": 6.86277, "twoHundredDayAverage": 6.2673464, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "tradeable": false, "enterpriseValue": 10044490, "profitMargins": 0.0, "floatShares": 829851, "sharesOutstanding": 2278620, "sharesShort": 36165, "sharesShortPriorMonth": 51030, "sharesShortPreviousMonthDate": 1752537600, "dateShortInterest": 1755216000, "sharesPercentSharesOut": 0.0159, "heldPercentInsiders": 0.60566, "heldPercentInstitutions": 0.04168, "shortRatio": 0.88, "shortPercentOfFloat": 0.0416, "impliedSharesOutstanding": 2278620, "bookValue": -0.074, "lastFiscalYearEnd": 1743379200, "nextFiscalYearEnd": 1774915200, "mostRecentQuarter": 1743379200, "netIncomeToCommon": -6767000, "trailingEps": -5.72, "forwardEps": -0.52, "lastSplitFactor": "1:20", "lastSplitDate": 1723680000, "enterpriseToEbitda": -1.36, "52WeekChange": -0.2798165, "SandP52WeekChange": 0.19736934, "exchange": "NCM", "quoteType": "EQUITY", "symbol": "PRTG", "underlyingSymbol": "PRTG", "shortName": "Portage Biotech Inc.", "longName": "Portage Biotech Inc.", "firstTradeDateEpochUtc": 916929000, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "c85b618a-5b14-3e35-9d8d-d4e5ddb2236b", "messageBoardId": "finmb_233586353", "gmtOffSetMilliseconds": -14400000, "currentPrice": 6.81, "recommendationKey": "none", "totalCash": 1670000, "totalCashPerShare": 0.733, "ebitda": -7383000, "totalDebt": 0, "quickRatio": 1.529, "currentRatio": 2.023, "returnOnAssets": -0.92688006, "returnOnEquity": -5.41807, "freeCashflow": -3330125, "operatingCashflow": -5462000, "grossMargins": 0.0, "ebitdaMargins": 0.0, "operatingMargins": 0.0, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2025-11-01"}]